Key result
Canakinumab cuts vascular events by lowering inflammation without altering lipid levels.
Answers are grounded in this paper and cite their sources.
Inflammation has long been associated with the initiation and progression of atherosclerosis. Indeed, statin-treated post-myocardial infarction patients with 'residual inflammatory risk' [defined by a persistently elevated high-sensitivity C-reactive protein (hsCRP)] have higher rates of recurrent cardiovascular events, and are twice as common as patients with 'residual cholesterol risk' [defined by a persistently elevated low-density lipoprotein (LDL) cholesterol]. 1 Yet, until presentation of data from the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) at the 2017 European Society of Cardiology meeting in Barcelona, the clinical community had no evidence that reducing inflammation in the absence of lipid lowering could reduce vascular event rates.
No takes yet. Share an insight, caveat, or question.
Paul M. Ridker (2017) conducted an editorial in Post-myocardial infarction with residual inflammatory risk. Canakinumab was evaluated. Canakinumab administration reduces vascular event rates by lowering inflammation in the absence of lipid lowering.
Synapse has enriched 10 related papers. Consider them for comparative context: